New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
19:40 EDTINCY, INCY, INCYIncyte to hold an investor briefing
Management holds an Investor Briefing, in conjunction with ASCO, to recap Phase 2 Trial of Ruxolitinib in pancreatic cancer and Phase 1/2 trial of INCB24360 + Ipilimumab in Chicago on June 2 at 7:45 pm. Webcast Link
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
07:33 EDTINCYIncyte says clinical portfolio to be featured in 23 abstract presentations
Incyte Corporation (INCY) announced that 23 abstracts detailing studies from its clinical development pipeline, including those conducted by Incyte, Novartis (NVS) and independent investigators, will be presented at the 2015 American Society of Clinical Oncology and European Hematology Association annual meetings. These conferences will take place from May 29th – June 2nd in Chicago, IL and June 11th – 14th in Vienna, Austria. “The abstracts to be presented at ASCO and EHA showcase the depth and breadth of our development pipeline in oncology, as well as the success of our collaboration with Novartis,” stated Rich Levy, MD, Incyte’s Chief Drug Development Officer. “Incyte is committed to translating R&D excellence into new medicines which can improve patients’ lives, and these data, including novel:novel combinations from within our portfolio, provide further evidence of our ongoing progress.”
May 19, 2015
07:22 EDTINCYIncyte has a conference call hosted by JPMorgan
Subscribe for More Information
May 14, 2015
08:50 EDTINCYIncyte data promising, says SunTrust
SunTrust believes that the data for Incyte's JAK1/PI3K combination in NHL and HL is promising. The firm says that the combo shows early signs of activity in B cell malignancies. It keeps a $120 price target and Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use